| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (NCT05417594) | AstraZeneca | 2022-06-24 |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies (NCT05469919) | AstraZeneca | 2022-06-09 |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors (NCT05315167) | Zhuhai Yufan Biotechnologies Co., Ltd | 2022-05-30 |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (NCT05159700) | Zhuhai Yufan Biotechnologies Co., Ltd | 2022-03-31 |
| A Phase I Open-label Study for Subjects With Advanced Malignancies (NCT04136834) | Athenex, Inc. | 2021-04-21 |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies (NCT04521413) | Treadwell Therapeutics, Inc | 2020-08-31 |
| Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies (NCT02347228) | Oneness Biotech Co., Ltd. | 2020-08-28 |
| A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (NCT04353102) | Eucure (Beijing) Biopharma Co., Ltd | 2020-04-22 |
| A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies (NCT03980821) | AstraZeneca | 2019-07-04 |
| A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients (NCT03736473) | AstraZeneca | 2018-11-07 |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies (NCT03394144) | AstraZeneca | 2018-01-30 |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies (NCT03363893) | Carrick Therapeutics Limited | 2017-11-14 |
| An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (NCT03084471) | AstraZeneca | 2017-06-05 |
| A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (NCT02740985) | AstraZeneca | 2016-06-17 |
| Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment (NCT02350868) | Taipei Medical University | 2015-04-24 |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies (NCT02575651) | Jiangsu HengRui Medicine Co., Ltd. | 2015-04-01 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies (NCT02398747) | AstraZeneca | 2015-03-17 |
| Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours (NCT02260661) | AstraZeneca | 2014-11-01 |
| A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline (NCT02080078) | AHS Cancer Control Alberta | 2014-09-01 |
| Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas (NCT01800630) | InnoPharmax Inc. | 2013-04-01 |
| Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies (NCT01813474) | AstraZeneca | 2013-03-25 |
| Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma (NCT01588548) | AstraZeneca | 2012-07-01 |
| Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer (NCT01605916) | AstraZeneca | 2012-06-01 |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects (NCT01340040) | AstraZeneca | 2011-07-01 |
| Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors (NCT01455584) | Hanmi Pharmaceutical Company Limited | 2011-06-01 |
| Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies (NCT01351350) | Millennium Pharmaceuticals, Inc. | 2011-02-28 |
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient (NCT01213160) | AstraZeneca | 2010-11-01 |
| A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. (NCT01219543) | AstraZeneca | 2010-11-01 |
| A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies (NCT01103791) | Samyang Biopharmaceuticals Corporation | 2010-04-01 |
| A Study of MEDI-575 in Patients With Advanced Solid Malignancies (NCT01102400) | AstraZeneca | 2010-03-01 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 (NCT01026402) | AstraZeneca | 2009-12-01 |
| Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours (NCT00979134) | AstraZeneca | 2009-10-21 |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies (NCT00997945) | AstraZeneca | 2009-10-01 |
| A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies (NCT00981721) | AstraZeneca | 2009-09-01 |
| Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 (NCT00973076) | AstraZeneca | 2009-08-01 |
| Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine (NCT00937664) | AstraZeneca | 2009-07-01 |
| A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies (NCT00871559) | Regeneron Pharmaceuticals | 2009-06-01 |
| A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors (NCT00879905) | Novartis Pharmaceuticals | 2009-05-01 |
| Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor (NCT01024283) | Royal Marsden NHS Foundation Trust | 2008-12-01 |
| Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918 (NCT00733031) | AstraZeneca | 2008-08-01 |
| Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (NCT00979563) | Hanmi Pharmaceutical Company Limited | 2008-07-01 |
| Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) (NCT00986843) | Hanmi Pharmaceutical Company Limited | 2008-06-01 |
| Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies (NCT00669097) | Novartis Pharmaceuticals | 2008-04-01 |
| Study of AZD8931 in Patients With Advanced Solid Malignancies (NCT00637039) | AstraZeneca | 2008-02-01 |
| Open Label, Dose Escalation Phase I Study of AZD2281 (NCT00572364) | AstraZeneca | 2007-11-01 |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies (NCT00351325) | Bristol-Myers Squibb | 2007-09-01 |
| Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan (NCT00473616) | AstraZeneca | 2007-05-01 |
| Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies (NCT00295243) | Mayo Clinic | 2004-09-01 |